Latest News

STAT Plus: Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

Some additional thoughts and comments on Moderna, its coronavirus vaccine, the stock’s valuation and Monday night’s $1.3 billion stock sale:

Of course, Moderna raised money. It was only one week ago that I described Moderna’s $23 billion enterprise value as “astonishingly high” for a company with no approved products and no appreciable revenue. Monday, it was $29 billion, with the stock reaching another all-time high of $80 per share, or four times the price from the beginning of the year.

Continue to STAT Plus to read the full story…

Source link

Related posts

Health Tip: Warning Signs of Suicide


New method to analyze cell membrane complexes could revolutionize the way we study diseases


Cancer Risk May Rise After Heart Attack


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy